Aichi Cancer Center

Nagoya, Aiti [Aichi] 464-8681

0 studies enrolling now · 2 studies all time

What they study most

Adjuvant, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, NSCLC, Stage IB-IIIA, Post-surgical, Uncommon EGFR Mutations

Studies at this site

• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling